Introduction: In 2013, the World Health Organization (WHO) recommended scaling up of routine viral load (VL) monitoring for patients on antiretroviral therapy (ART) in resource-limited settings [1] . During the transition phase from no VL-testing at all to routine VL-monitoring, targeted VL for groups at particular risk of virologic failure (VF) may be an option [2] . We present sociodemographic and clinical risk factors for VF in a cohort in rural Lesotho with no access to VL prior to the study. Materials and Methods: Data derive from a cross-sectional study providing multi-disease screening as well as VL testing to adult patients ( ]16 years old) on first-line ART ]6 months [3] . VF was defined as VL ]1000 copies/mL. Assessed potential predictors of VF were: (1) socio-demographic (sex, age, wealth-quintile, education, employment status, disclosure of HIV status to environment, travel-time to facility); (2) treatment history (history of treatment interruption 2 days, previous drug substitution within first-line ART, time on ART, ART-base and -backbone); (3) adherence (pill count) and (4) clinical (clinical or immunological failure as defined by WHO guidelines [1] , presence of papular pruritic eruption (PPE)). All variables with association to VF in univariate analysis were included in a multivariate logistic regression reporting adjusted Odds ratios (aOR). Results: Data from 1,488 patients were analyzed. Overall VF-prevalence was 6.9% (95% CI 5.7Á8.3). In univariate analysis, the following were associated with VF: age B30, lower wealth-quintile, no primary education, history of treatment interruption, nevirapine-base, zidovudine-backbone, history of drug substitution, travel-time to clinic ]2 hours, disclosure of HIV status to B5 persons, clinical failure, presence of PPE and immunological failure. In multivariate analysis, 6 out of the above 12 variables were independent predictors: age B30 years (aOR: 2.4; 95% CI 1.1Á5.3, p00.029), history of treatment interruption (2.5; 1.3Á 4.7, p00.005), PPE (6.9; 2.5Á18.9, pB0.001), immunological failure (11.5; 5.7Á23.2, pB0.001), history of drug substitution (1.9; 1.0Á3.7, p00.043), disclosure of HIV status to B5 persons (1.8; 1.1Á3.1, p00.03). Conclusion: In this cohort in rural Lesotho, several socio-demographic and clinical predictors were associated with VF. Particularly age B30 years, history of treatment interruption, PPE and immunological failure were strongly associated with VF. These patients may be prioritized for targeted VL-testing.
